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Abstract
Background: Dry eye is usually managed by conventional medical interventions such as
artificial tears, anti-inflammatory drugs and surgical treatment. However, since dry eye is one of
the most frequent ophthalmologic disorders, safer and more effective methods for its treatment
are necessary, especially for vulnerable patients. Acupuncture has been widely used to treat
patients with dry eye. Our aim is to evaluate the effectiveness and safety of acupuncture for this
condition.
Methods/Design: A randomised, patient-assessor blinded, sham (non-acupuncture point,
shallow acupuncture) controlled study was established. Participants allocated to verum
acupuncture and sham acupuncture groups will be treated three times weekly for three weeks
for a total of nine sessions per participant. Seventeen points (GV23; bilateral BL2, GB4, TE23, Ex1
(Taiyang), ST1 and GB20; and left SP3, LU9, LU10 and HT8 for men, right for women) have been
selected for the verum acupuncture; for the sham acupuncture, points have been selected that do
not coincide with a classical acupuncture point and that are located close to the verum points,
except in the case of the rim of the eye. Ocular surface disease index, tear film breakup time, the
Schirmer I test, medication quantification scale and general assessment of improvement will be used
as outcome variables for evaluating the effectiveness of acupuncture. Safety will also be assessed at
every visit. Primary and secondary outcomes will be assessed four weeks after screening. All
statistical analyses will be performed using analysis of covariance.
Discussion: The results of this trial will be used as a basis for clarifying the efficacy of acupuncture
for dry eye.
Trial registration: ClinicalTrials.gov NCT00969280.
Background
Dry eye is one of the most frequently occurring
opthalmological health problems worldwide. The pre-
valence of dry eye is estimated to be in the range of 5%
to 35% and its incidence has recently been increasing [1].
According to a recent survey, over 20% of outpatients in
ophthalmologic clinics in Korea were diagnosed with dry
eye [2]. The burden of dry eye involves not only
problems with common activities such as reading,
carrying out professional work, using the computer,
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Open Accesswatching television, and driving [3], but also widespread
limitations in the activities of daily life, bodily pain,
discomfort and lower energy and vitality [4].
Currently, the use of artificial tears and lifestyle
modifications are the most common choices in manage-
ment of patients with mild dry eye [5]. In moderate and
severe cases, anti-inflammatory medications such as
corticosteroids, cyclosporine and tetracycline are recom-
mended [6]. However, preservatives in artificial tears
may exacerbate ocular surface inflammation and the
safety of anti-inflammatory treatment is not well
established [6,7]. In this context, various treatments in
complementary and alternative medicine (CAM) are
administered for dry eye in clinical practice [8].
Acupuncture, one of the most popular CAM interven-
tions, showed some favourable effects over artificial tears
for dry eye when administered alone [9,10] or con-
comitantly [11,12] with artificial tears in several rando-
mised controlled trials (RCTs). The evidence obtained
from these trials is quite limited because all of these
RCTs were conducted under high risk of bias including
uncertainty of blinding, inadequate randomness of
allocation of patients, failure to consider sample size
and inappropriate control groups. Therefore, well-
designed RCTs are needed to establish the efficacy of
acupuncture for dry eye.
Study aims
This study aims to evaluate the effectiveness and safety of
acupuncture treatment for dry eye. The null hypothesis
of this study is “the change in dry eye symptoms after
verum acupuncture treatment is equal to the change in
dry eye symptoms after sham acupuncture treatment.”
Methods/Design
This study is a randomised, patient-assessor blinded,
sham acupuncture controlled trial. Enrolled participants
will be randomly allocated to either a verum acupunc-
ture or a sham acupuncture group and will receive nine
sessions of treatment over a three-week period. Partici-
pants will be examined for signs and symptoms of dry
e y eb e f o r ea n da f t e rt r e a t m e n t( F i g u r e1 ) .
Recruitment
We will recruit participantsb ya d v e r t i s e m e n t si nl o c a l
newspapers and on websites of local universities and
companies in Daejeon province, Korea. Respondents will
be contacted by clinical trial coordinators (CRC) to
determine eligibility in a telephone pre-screening. If the
applicant is eligible according to the study criteria, he or
she will be invited to the clinical research centre of KIOM
(Korea Institute of Oriental Medicine) and examined for
eligibility by physicians and ophthalmologists.
Inclusion and exclusion criteria
Eligible participants of both sexes who have moderate to
severe levels of dry eye will be enrolled according to the
inclusion and exclusion criteria. In addition to abnormal
ophthalmological test results (Tear Film Break-Up Time
and Schirmer I test), they must have symptoms of dry
eye such as ocular itching, ocular foreign body sensation,
ocular pain, ocular dryness, or vision problems, which
may include blurred vision or a sensation of photo-
phobia. Special medical conditions and conditions that
can increase adverse event risk or might be expected to
mislead interpretation of the outcome after acupuncture
treatment comprise the exclusion criteria (Appendix 1).
Sample size and randomisation
We wished to estimate the sample size that would suffice
to detect an 18 point difference in the Ocular Surface
Disease Index (OSDI) between the verum and control
groups. In our previous uncontrolled acupuncture study,
the standard deviation of OSDI was estimated to be
19.342 [13]. If we apply a two-sided 5% significance
level, 90% power and 10% dropout rate, the calculated
required sample size is approximately 21 participants in
each group, according to the following equation:
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An expert on statistics from KIOM who has no direct
contact with the study participants will conduct rando-
misation of participants. He/she will generate random
numbers with block randomisation using the SAS
statistical package (Version 9.1.3; SAS institute Inc.).
The block size will be concealed from other researchers
and the randomisation table will not be available for
assessment by anyone else involved in the study.
Opaque sealed envelopes containing serial numbers will
be delivered to the clinical trial centre. Before the
random assignment, all participants will be informed
that they will be allocated to one of two groups. Random
allocation will be conducted at visit 2. Random numbers
with corresponding participants will be determined in
the order of the time of second visit and will be opened
by acupuncture practitioners. The allocation result will
not be announced to the participants until the last visit
of the last randomised participant.
The success of blinding will be assessed at each
participant’s last visit. Researchers who did not partici-
pate in the acupuncture treatment and who are blinded
to the allocation results will perform the outcome
assessment.
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Acupuncture of both groups will be carried out by
licensed oriental medicine physicians who have been
trained for four years and have at least five years of
clinical experience in acupuncture treatment. Acupunc-
ture practitioners will be required to attend a one-day
training course on this study.
Verum acupuncture group
Standardised acupuncture treatment will be applied to
patients in the verum acupuncture group. Acupuncture
points were selected according to the opinions of
professional acupuncturists in KIOM based on a pub-
lication about acupuncture treatment for dry eye [14].
Seventeen acupuncture points represented by bilateral
BL2, GB4, TE23, Ex 1 (Taiyang), ST1, and GB20 and
unilateral SP3, LU9, LU10, HT8 and GV23 were chosen.
F o rS P 3 ,L U 9 ,L U 1 0 ,a n dH T 8 ,m a l e sw i l lb et r e a t e do n
the left side and females on the right side according to
traditional Korean medicine theory. Disposable, 20
mm*30 mm-size acupuncture needles (Dongbang Co.,
Korea) will be used. With the exception of Ex1 (Taiyang),
each point will be selected and treated in accordance
with the WHO Standard Acupuncture Point Locations in
the Western Pacific Regional guideline [15]. After
insertion, needles will be twisted several times until the
participants feel ‘de qi’ sensation and left for 20 minutes.
Each participant will undergo a total of nine sessions
(three times per week for three weeks).
Sham acupuncture group (non-acupuncture point shallow
penetration group)
A sham acupuncture point corresponding to each verum
acupuncture point was selected. The principle of sham
point selection is that the sham point should not be a
classical acupuncture point and should, except for points
o nt h er i mo ft h ee y e ,b el o c a t e dc l o s et ot h ev e r u m
point. The selected sham points are as follows: both
points 2 cm lateral to ST4, 2 cm below ST7, at the
parietal eminence of head, 2 cm internal to ST9, 10 cm
internal to BL57, 1.5 cm internal to ST36, one point at
the left middle point of the bicepsbrachii muscle belly,
Figure 1
Study Flow Chart.
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and one point located between the Lt. 3
rd and 4
th
metatarsophalangeal joints. After shallow penetration of
the skin at each site with no manipulation for ‘de qi,’ the
needle is left for 20 minutes. Every participant in the
sham acupuncture group will be treated three times per
week for three weeks.
Permitted and prohibited concomitant treatments
Participants will be permitted to use artificial tears
depending on symptomseverity; thefrequency anddosage
of use must be recorded. However, the use of artificial tears
during the two hours prior to acupuncture treatment will
be prohibited. Drugs or tear supplements such as
cyclosporine, corticosteroids, biological tear substitutes
and oestrogen will be prohibited. The wearing of contact
lenses will be prohibited during the trial period.
Primary outcome measurement
OSDI will be used as the primary outcome variable. This
questionnaire is a 12-item instrument for assessment of
ocular irritation and impact on visual function in dry eye
sufferers. It can provide quantifiable results of dry eye
symptom frequency and vision-related functioning [16].
Each question will be answered on a scale of 0 to 4,
w h e r e0m e a n sn o n eo ft h et i m e ;1 ,s o m eo ft h et i m e ;2 ,
half of the time; 3, most of the time; and 4, all of the
time. Each patient’s OSDI score will be calculated on the
basis of the following formula: OSDI = [(sum of scores
for all questions answered)*100]/[(total number of
questions answered)*4]. We will use the Korean version
of the OSDI questionnaire [17].
Secondary outcome measurement
The visual analogue scale (VAS) for self-assessment of
ocular discomfort will be used. Self-reports on ocular
symptoms concomitant with dry eye will be obtained
for such conditions as ocular itching, foreign body
sensation, burning, pain and dryness as well as for
blurred vision, sensation of photophobia, ocular redness
and sensation of tearing. Each participant will record a
score indicating his or her total level of discomfort on a
100 mm horizontal line.
Tear Film Break-Up Time (TFBUT) and the Schirmer I test
with anaesthesia will be used as additional secondary
outcome variables. TFBUT is a method for observing tear
film stability. Sodium fluorescein (2.5%) will be
instilled in both eyes and the tear break-up time (the
interval between the last complete blink and the first
appearance of a dry spot or disruption in the tear film)
will be measured [18]. The Schirmer I test with
anaesthesia is a method for checking basic tear secretion.
Schirmer test paper (Color Bar™ Eagle Vision, USA) will
be inserted on the lateral third of the lower eyelid with
the participant’s eye closed for five minutes. Each test
will be performed by a single ophthalmologist.
Medication Quantification Scale (MQS) and General
Assessment of Improvement will also be used as
secondary outcome variables. The total frequency and
dosage of artificial tears will be checked. At the final visit
of each participant, both participant and practitioner will
assess improvements in ocular symptoms. ‘Excellent’
indicates the presence of no symptoms related to dry eye
and much improvement in daily life; ‘Good’ means that
a few symptoms related to dry eye are present but that
the condition is better than before treatment; ‘Fair’
m e a n st h a ts e v e r a ls y m p t o m sr e l a t e dt od r ye y ea r e
present but that the condition is a little improved; ‘Poor’
means that there is no change compared with before
treatment; ‘Aggravation’ means that symptoms are worse
than they were before treatment (Table 1).
Statistical analysis
We will conduct analysis on an intention-to-treat basis
(significance level p < 0.05) using the SAS statistical
package program (ver. 9.1.3). Baseline characteristics will
be shown as mean ± standard deviation (SD) for
continuous data including age, previous duration of
dry eye, OSDI, VAS for self-assessment of ocular
discomfort, TFBUT and Schirmer’sIt e s tv a l u e .A sf o r
participants’ gender, n (%) of male and female in each
group will be shown as baseline characteristics. We will
conduct between-group comparision in baseline using
two-sample t-test or Wilcoxon rank sum test for
continuous data and using Chi-square test or Fisher’s
exact test for gender composition considering p < 0.05 as
statistically significant.
For primary and secondary outcome measures, the mean
differences from baseline values to the end of treatment
will be compared using two-sample t-test or Wilcoxon
rank sum test. If any imbalances in baseline character-
istics between groups are encountered, we will conduct
ANCOVA (analysis of covariance) using these imbal-
anced variables as covariates and allocated group as fixed
factor.
Adverse events
We define adverse events as unfavourable or unintended
signs, symptoms or disease occurring after treatment that
are not necessarily related to the acupuncture interven-
tion. Acupuncture-related adverse events are defined as
local symptoms including bruising and pain for over two
weeks at acupuncture points, peripheral neuritis and
swelling, redness and itching for over three days,
systemic symptoms including dizziness and palpitation,
Trials 2009, 10:112 http://www.trialsjournal.com/content/10/1/112
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three days, anxiety or fear for over 60 hours, and
hypersensitivity for over three days. In case of serious
medical problems, other symptoms could be included in
adverse events. In every visit, adverse events will be
reported by participants and examined by the practi-
tioner.
Ethics
Written consent will be obtained from each participant.
This study protocol was approved by the institutional
review board of Daejeon University hospital.
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Appendix 1. Inclusion and Exclusion Criteria
Inclusion Criteria
Patients who have had dry eye syndrome in a single eye
or in both eyes (ICD-10: H04.1).
He or she must have both of the conditions below:
￿ Patients who have been having symptoms such as
ocular itching, ocular foreign body sensation, ocular
burning, ocular pain, ocular dryness, blurred vision,
sensation of photophobia, ocular redness or sensa-
tion of tearing
￿ Patients whose Tear Film Break-Up Time (TFBUT) is
below 10 seconds and measured tear amount is
b e l o w1 0m m / 5s e cb yt h eS c h i r m e rIt e s t
Exclusion Criteria
￿ Those who have defects of eyelid or eyelashes
￿ Those who have acute infection of the eyelid,
eyeball or eye accessories
￿ Those who have Stevens-Johnson syndrome or
pemphigoids
￿ Those who have Vitamin A deficiency
￿ Those who have any eye or accessory defect due to
external injuries
￿ Those who have undergone any surgical operation
r e l a t e dt ot h ee y ei nt h el a s tt h r e em o n t h s
￿ Those who are using contact lenses
￿ Those who have any difficulties of eye opening or
eye closing due to facial palsy
Table 1: Schedule for treatment and outcome measurement
Period screening F/U
V i s i t 1 23 456 789 1 0 1 1
Week 1st 2nd 3rd Visit10+
1 week+
3d a y s
Informed consent ν
Demographic characteristics ν
Medical History ν
Physical examination ν
Random Allocation ν
Acupuncture Treatment νν ννν ννν ν
Symptom score ν νν ννν ννν ν ν
OSDI νν ν ν ν
Schirmer I test ν ν
TFBUT ν ν
MQS νν ννν ννν ν ν
General assessment
(patient/doctor)
ν
Blinding Assessment ν ν
Safety Assessment νν ννν ννν ν ν
OSDI: Ocular Surface Disease Index; TFBUT: Tear Film Break-up Time; MQS: Medication Quantification Scale.
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surgery
￿ Those who have used any type of anti-inflamma-
tory eye drops in the last two weeks (steroids,
cyclosporin or autologous serum eye drops)
￿ Those who have systemic immune problems
￿ Those who are pregnant or plan to become
pregnant
￿ Those who are not appropriate for this study
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